Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Baker GJ, Castro MG, Lowenstein PR. Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells. J Vis Exp 2015. [PMID: 26650233 DOI: 10.3791/53676] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open

For:	Baker GJ, Castro MG, Lowenstein PR. Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells. J Vis Exp 2015. [PMID: 26650233 DOI: 10.3791/53676] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open

Number

Cited by Other Article(s)

Daisy Precilla S, Kuduvalli SS, Biswas I, Bhavani K, Pillai AB, Thomas JM, Anitha TS. Repurposing synthetic and natural derivatives induces apoptosis in an orthotopic glioma-induced xenograft model by modulating WNT/β-catenin signaling. Fundam Clin Pharmacol 2023;37:1179-1197. [PMID: 37458120 DOI: 10.1111/fcp.12932] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 05/09/2023] [Accepted: 06/09/2023] [Indexed: 07/18/2023]

Alghamri MS, Banerjee K, Mujeeb AA, Mauser A, Taher A, Thalla R, McClellan BL, Varela ML, Stamatovic SM, Martinez-Revollar G, Andjelkovic AV, Gregory JV, Kadiyala P, Calinescu A, Jiménez JA, Apfelbaum AA, Lawlor ER, Carney S, Comba A, Faisal SM, Barissi M, Edwards MB, Appelman H, Sun Y, Gan J, Ackermann R, Schwendeman A, Candolfi M, Olin MR, Lahann J, Lowenstein PR, Castro MG. Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy. ACS NANO 2022;16:8729-8750. [PMID: 35616289 PMCID: PMC9649873 DOI: 10.1021/acsnano.1c07492] [Citation(s) in RCA: 41] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]

Abstract

Glioblastoma (GBM) is an aggressive primary brain cancer, with a 5 year survival of ∼5%. Challenges that hamper GBM therapeutic efficacy include (i) tumor heterogeneity, (ii) treatment resistance, (iii) immunosuppressive tumor microenvironment (TME), and (iv) the blood-brain barrier (BBB). The C-X-C motif chemokine ligand-12/C-X-C motif chemokine receptor-4 (CXCL12/CXCR4) signaling pathway is activated in GBM and is associated with tumor progression. Although the CXCR4 antagonist (AMD3100) has been proposed as an attractive anti-GBM therapeutic target, it has poor pharmacokinetic properties, and unfavorable bioavailability has hampered its clinical implementation. Thus, we developed synthetic protein nanoparticles (SPNPs) coated with the transcytotic peptide iRGD (AMD3100-SPNPs) to target the CXCL2/CXCR4 pathway in GBM via systemic delivery. We showed that AMD3100-SPNPs block CXCL12/CXCR4 signaling in three mouse and human GBM cell cultures in vitro and in a GBM mouse model in vivo. This results in (i) inhibition of GBM proliferation, (ii) reduced infiltration of CXCR4⁺ monocytic myeloid-derived suppressor cells (M-MDSCs) into the TME, (iii) restoration of BBB integrity, and (iv) induction of immunogenic cell death (ICD), sensitizing the tumor to radiotherapy and leading to anti-GBM immunity. Additionally, we showed that combining AMD3100-SPNPs with radiation led to long-term survival, with ∼60% of GBM tumor-bearing mice remaining tumor free after rechallenging with a second GBM in the contralateral hemisphere. This was due to a sustained anti-GBM immunological memory response that prevented tumor recurrence without additional treatment. In view of the potent ICD induction and reprogrammed tumor microenvironment, this SPNP-mediated strategy has a significant clinical translation applicability.

Collapse

Affiliation(s)

Mahmoud S Alghamri Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Kaushik Banerjee Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Anzar A Mujeeb Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Ava Mauser Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA
Ayman Taher Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Rohit Thalla Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Brandon L McClellan Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Maria L Varela Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Svetlana M Stamatovic Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA
Gabriela Martinez-Revollar Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA
Anuska V Andjelkovic Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA
Jason V Gregory Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA
Padma Kadiyala Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Alexandra Calinescu Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Jennifer A Jiménez Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA
April A Apfelbaum Seattle Children’s Research Institute, University of Washington Seattle, WA, 98101 Cancer Biology Ph.D. Program, University of Michigan, Ann Arbor, MI 48109, USA
Elizabeth R Lawlor Seattle Children’s Research Institute, University of Washington Seattle, WA, 98101
Stephen Carney Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Andrea Comba Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Syed Mohd Faisal Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Marcus Barissi Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Marta B. Edwards Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Henry Appelman Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA
Yilun Sun Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH 44106
Jingyao Gan Department of Pharmaceutical Sciences, University of Michigan College of Pharmacy, Ann Arbor, MI 48109, USA
Rose Ackermann Department of Pharmaceutical Sciences, University of Michigan College of Pharmacy, Ann Arbor, MI 48109, USA
Anna Schwendeman Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA Department of Pharmaceutical Sciences, University of Michigan College of Pharmacy, Ann Arbor, MI 48109, USA
Marianela Candolfi Instituto de Investigaciones Biomédicas (INBIOMED, UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
Michael R. Olin Department of Pediatrics, University of Minnesota, Minneapolis MN 55455 Masonic Cancer Center, University of Minnesota, Minneapolis MN 55455
Joerg Lahann Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA Corresponding Authors:, ,
Pedro R. Lowenstein Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA Biosciences Initiative in Brain Cancer, University of Michigan, Ann Arbor, MI 48109, USA Corresponding Authors:, ,
Maria G. Castro Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA Biosciences Initiative in Brain Cancer, University of Michigan, Ann Arbor, MI 48109, USA Corresponding Authors:, ,

Collapse

Alghamri MS, McClellan BL, Avvari RP, Thalla R, Carney S, Hartlage MS, Haase S, Ventosa M, Taher A, Kamran N, Zhang L, Faisal SM, Núñez FJ, Garcia-Fabiani MB, Al-Holou WN, Orringer D, Hervey-Jumper S, Heth J, Patil PG, Eddy K, Merajver SD, Ulintz PJ, Welch J, Gao C, Liu J, Núñez G, Hambardzumyan D, Lowenstein PR, Castro MG. G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. SCIENCE ADVANCES 2021;7:eabh3243. [PMID: 34586841 PMCID: PMC8480930 DOI: 10.1126/sciadv.abh3243] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Accepted: 08/06/2021] [Indexed: 05/24/2023]

Affiliation(s)

Mahmoud S. Alghamri Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Brandon L. McClellan Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA Graduate Program in Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Ruthvik P. Avvari Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Rohit Thalla Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Stephen Carney Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Margaret S. Hartlage Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Santiago Haase Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Maria Ventosa Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Ayman Taher Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Neha Kamran Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Li Zhang Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Syed Mohd Faisal Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Felipe J. Núñez Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
María Belén Garcia-Fabiani Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Wajd N. Al-Holou Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Daniel Orringer Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Shawn Hervey-Jumper Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143, USA
Jason Heth Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Parag G. Patil Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Karen Eddy Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Sofia D. Merajver Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Peter J. Ulintz Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Joshua Welch Department of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Chao Gao Department of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Jialin Liu Department of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Gabriel Núñez Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Dolores Hambardzumyan Department of Oncological Sciences, The Tisch Cancer Institute, and Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Pedro R. Lowenstein Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
Maria G. Castro Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA

Collapse

Shah D, Comba A, Faisal SM, Kadiyala P, Baker GJ, Alghamri MS, Doherty R, Zamler D, Nuñez G, Castro MG, Lowenstein PR. A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1. Oncoimmunology 2021;10:1939601. [PMID: 34249474 PMCID: PMC8244780 DOI: 10.1080/2162402x.2021.1939601] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Accepted: 05/31/2021] [Indexed: 02/08/2023] Open

Affiliation(s)

Diana Shah Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA Rogel Cancer Center, University of Michigan, Ann Arbor, MIUSA Cancer Biology Training Program, University of Michigan Medical School, Ann Arbor, MI, USA
Andrea Comba Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA Rogel Cancer Center, University of Michigan, Ann Arbor, MIUSA Cancer Biology Training Program, University of Michigan Medical School, Ann Arbor, MI, USA
Syed M. Faisal Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA Rogel Cancer Center, University of Michigan, Ann Arbor, MIUSA Cancer Biology Training Program, University of Michigan Medical School, Ann Arbor, MI, USA
Padma Kadiyala Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA Rogel Cancer Center, University of Michigan, Ann Arbor, MIUSA Cancer Biology Training Program, University of Michigan Medical School, Ann Arbor, MI, USA
Gregory J. Baker Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA Rogel Cancer Center, University of Michigan, Ann Arbor, MIUSA Cancer Biology Training Program, University of Michigan Medical School, Ann Arbor, MI, USA
Mahmoud S. Alghamri Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA Rogel Cancer Center, University of Michigan, Ann Arbor, MIUSA Cancer Biology Training Program, University of Michigan Medical School, Ann Arbor, MI, USA
Robert Doherty Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA Rogel Cancer Center, University of Michigan, Ann Arbor, MIUSA Cancer Biology Training Program, University of Michigan Medical School, Ann Arbor, MI, USA
Daniel Zamler Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA Rogel Cancer Center, University of Michigan, Ann Arbor, MIUSA Cancer Biology Training Program, University of Michigan Medical School, Ann Arbor, MI, USA
Gabriel Nuñez Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
Maria G. Castro Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA Rogel Cancer Center, University of Michigan, Ann Arbor, MIUSA Cancer Biology Training Program, University of Michigan Medical School, Ann Arbor, MI, USA
Pedro R. Lowenstein Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA Rogel Cancer Center, University of Michigan, Ann Arbor, MIUSA Cancer Biology Training Program, University of Michigan Medical School, Ann Arbor, MI, USA

Collapse

Wouters R, Bevers S, Riva M, De Smet F, Coosemans A. Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma. Cancers (Basel) 2020;13:E19. [PMID: 33374542 PMCID: PMC7793150 DOI: 10.3390/cancers13010019] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 12/19/2020] [Accepted: 12/20/2020] [Indexed: 12/12/2022] Open

Byrd AS, Dina Y, Okoh UJ, Quartey QQ, Carmona-Rivera C, Williams DW, Kerns ML, Miller RJ, Petukhova L, Naik HB, Barnes LA, Shipman WD, Caffrey JA, Sacks JM, Milner SM, Aliu O, Broderick KP, Kim D, Liu H, Dillen CA, Ahn R, Frew JW, Kaplan MJ, Kang S, Garza LA, Miller LS, Alavi A, Lowes MA, Okoye GA. Specimen Collection for Translational Studies in Hidradenitis Suppurativa. Sci Rep 2019;9:12207. [PMID: 31434914 PMCID: PMC6704132 DOI: 10.1038/s41598-019-48226-w] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2018] [Accepted: 07/22/2019] [Indexed: 12/13/2022] Open

Affiliation(s)

A S Byrd Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA. Department of Dermatology, Howard University College of Medicine, Washington, DC, 20060, USA.
Y Dina Meharry Medical College, Nashville, TN, 37208, USA
U J Okoh Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
Q Q Quartey University of Maryland School of Medicine, Baltimore, MD, 21201, USA
C Carmona-Rivera Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 20892, USA
D W Williams Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA
M L Kerns Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
R J Miller Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
L Petukhova Departments of Dermatology and Epidemiology, Columbia University, New York, NY, 10032, USA
H B Naik Program for Clinical Research, Department of Dermatology, University of California San Francisco, San Francisco, CA, 94143-0808, USA
L A Barnes Stanford University School of Medicine, Stanford, CA, 94305, USA
W D Shipman Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program, New York, NY, 10065, USA
J A Caffrey Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
J M Sacks Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
S M Milner Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
O Aliu Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
K P Broderick Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
D Kim Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
H Liu Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
C A Dillen Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
R Ahn Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA
J W Frew Department of Dermatology, Liverpool Hospital, Sydney, NSW, 2170, Australia Ingham Institute of Applied Medical Research, Liverpool, Sydney, NSW, 2170, Australia University of New South Wales, Sydney, NSW, 2033, Australia
M J Kaplan Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 20892, USA
S Kang Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
L A Garza Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
L S Miller Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA
A Alavi Department of Medicine (Dermatology), University of Toronto, Toronto, Ontario, M1C 1A4, Canada Division of Dermatology, Women's College Hospital, Toronto, ON, M5S 1B2, Canada
M A Lowes The Rockefeller University, New York, NY, 10065, USA
G A Okoye Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA Department of Dermatology, Howard University College of Medicine, Washington, DC, 20060, USA

Collapse

Alghamri MS, Kamran N, Kadiyala P, Lowenstein PR, Castro MG. Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models. Methods Enzymol 2019;632:215-228. [PMID: 32000897 PMCID: PMC7038868 DOI: 10.1016/bs.mie.2019.05.047] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]

Alghamri MS, Núñez FJ, Kamran N, Carney S, Altshuler D, Lowenstein PR, Castro MG. Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models. Methods Enzymol 2019;631:91-106. [PMID: 31948569 PMCID: PMC7021207 DOI: 10.1016/bs.mie.2019.05.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/24/2024]

Guan X, Luo L, Begum G, Kohanbash G, Song Q, Rao A, Amankulor N, Sun B, Sun D, Jia W. Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2018;37:255. [PMID: 30333031 PMCID: PMC6192309 DOI: 10.1186/s13046-018-0923-z] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Accepted: 10/02/2018] [Indexed: 12/11/2022]

Abstract

Background

Sodium/hydrogen exchanger 1 (NHE1), encoded by the SLC9A1 gene (SoLute Carrier family 9A1) in humans, is the main H⁺ efflux mechanism in maintaining alkaline intracellular pH (pH_i) and Warburg effects in glioma. However, to date, there are no clinical studies exploring pharmacological inhibition of NHE1 protein in cancer treatment. In this study, we investigated NHE1 expression in gliomas and its relationship with glioma clinical outcome.

Methods

The Chinese Glioma Genome Atlas (CGGA) dataset containing transcriptome sequencing data of 325 glioma samples and the Cancer Genome Atlas (TCGA) with 698 glioma mRNAseq data were analyzed in this study. Mouse SB28 and GL26 intracranial syngeneic glioma models in C57BL/6 J mice were established to investigate NHE1 expression and impact of NHE1 protein inhibition with its inhibitor HOE642 on tumorigenesis and anti-PD1 therapy. Tumor angiogenesis, immunogenicity, and progression were assessed by immunofluorescence staining and flow cytometric profiling.

Results

Analysis of SLC9A1 mRNA expression in two data sets, CGGA and TCGA, reveals significantly higher SLC9A1 mRNA levels in higher grade gliomas. The SLC9A1 mRNA expression was especially enriched in isocitrate dehydrogenase (IDH)1/2 wild-type glioblastoma (GBM) and in mesenchymal glioma subtypes. Worsened survival probabilities were correlated with the elevated SLC9A1 mRNA levels in gliomas. The underlying mechanisms include promoting angiogenesis, and extracellular matrix remodeling. Increased SLC9A1 mRNA expression was also associated with tumor-associated macrophage accumulation. NHE1 inhibitor HOE642 reduced glioma volume, invasion, and prolonged overall survival in mouse glioma models. Blockade of NHE1 protein also stimulated immunogenic tumor microenvironment via activating CD8 T-cell accumulation, increasing expression of interferon-gamma (Ifng), and sensitized animals to anti-PD-1 therapy.

Conclusion

Our findings strongly suggest that NHE1 protein emerges as a marker for tumorigenesis and prognosis in glioma. Blocking NHE1 protein is a novel strategy for adjuvant anti-cancer therapies.

Electronic supplementary material

The online version of this article (10.1186/s13046-018-0923-z) contains supplementary material, which is available to authorized users.

Collapse

Affiliation(s)

Xiudong Guan Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing, 100050, China.,Chinese National Clinical Research Center for Neurological Diseases, Beijing, China.,Beijing Neurosurgical Institute, Beijing, China.,Chinese Glioma Genome Atlas Network, Beijing, 100050, China.,Department of Neurology, University of Pittsburgh, 7016 Biomedical Science Tower 3 3501 Fifth Ave., Pittsburgh, PA, 15260, USA
Lanxin Luo School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China.,Department of Neurology, University of Pittsburgh, 7016 Biomedical Science Tower 3 3501 Fifth Ave., Pittsburgh, PA, 15260, USA
Gulnaz Begum Department of Neurology, University of Pittsburgh, 7016 Biomedical Science Tower 3 3501 Fifth Ave., Pittsburgh, PA, 15260, USA.,Pittsburgh Institute for Neurodegenerative Disorders, University of Pittsburgh, Pittsburgh, PA, USA
Gary Kohanbash Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA
Qingkun Song Department of Science and Technology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Aparna Rao Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA
Nduka Amankulor Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA
Baoshan Sun School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China.,Pólo Dois Portos, Instituto National de Investigação Agrária e Veterinária, I.P., Quinta da Almoinha, Dois Portos, Portugal
Dandan Sun Department of Neurology, University of Pittsburgh, 7016 Biomedical Science Tower 3 3501 Fifth Ave., Pittsburgh, PA, 15260, USA. .,Pittsburgh Institute for Neurodegenerative Disorders, University of Pittsburgh, Pittsburgh, PA, USA.
Wang Jia Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing, 100050, China. .,Chinese National Clinical Research Center for Neurological Diseases, Beijing, China. .,Beijing Neurosurgical Institute, Beijing, China. .,Chinese Glioma Genome Atlas Network, Beijing, 100050, China.

Collapse

Baker GJ, Chockley P, Zamler D, Castro MG, Lowenstein PR. Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells. Oncoimmunology 2016;5:e1163461. [PMID: 27471637 DOI: 10.1080/2162402x.2016.1163461] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Revised: 03/02/2016] [Accepted: 03/04/2016] [Indexed: 10/22/2022] Open

Abstract

Malignant gliomas are resistant to natural killer (NK) cell immune surveillance. However, the mechanisms used by these cancers to suppress antitumor NK cell activity remain poorly understood. We have recently reported on a novel mechanism of innate immune evasion characterized by the overexpression of the carbohydrate-binding protein galectin-1 by both mouse and rat malignant glioma. Here, we investigate the cytokine profile of galectin-1-deficient GL26 cells and describe the process by which these tumors are targeted by the early innate immune system in RAG1(-/-) and C57BL/6J mice. Our data reveal that galectin-1 knockdown in GL26 cells heightens their inflammatory status leading to the rapid recruitment of Gr-1(+)/CD11b(+) myeloid cells and NK1.1(+) NK cells into the brain tumor microenvironment, culminating in tumor clearance. We show that immunodepletion of Gr-1(+) myeloid cells in RAG1(-/-) mice permits the growth of galectin-1-deficient glioma despite the presence of NK cells, thus demonstrating an essential role for myeloid cells in the clearance of galectin-1-deficient glioma. Further characterization of tumor-infiltrating Gr-1(+)/CD11b(+) cells reveals that these cells also express CCR2 and Ly-6C, markers consistent with inflammatory monocytes. Our results demonstrate that Gr-1(+)/CD11b(+) myeloid cells, often referred to as myeloid-derived suppressor cells (MDSCs), are required for antitumor NK cell activity against galectin-1-deficient GL26 glioma. We conclude that glioma-derived galectin-1 represents an important factor in dictating the phenotypic behavior of monocytic Gr-1(+)/CD11b(+) myeloid cells. Galectin-1 suppression may be a valuable treatment approach for clinical glioma by promoting their innate immune-mediated recognition and clearance through the concerted effort of innate myeloid and lymphoid cell lineages.

Collapse